Source: Pediatric Blood & Cancer. Conference titles: Congress of the International Society of Paediatric Oncology (SIOP). Unidade: FMRP
Subjects: OSTEOSSARCOMA, LINHAGEM CELULAR
ABNT
GAMERO, Angel Mauricio Castro et al. Antitumor effect of the dehydroxymethylepoxyquinomicin (DHMEQ), a novel nuclear factor-B inhibitor, in pediatric osteosarcoma cell lines. Pediatric Blood & Cancer. Hoboken: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 02 nov. 2024. , 2010APA
Gamero, A. M. C., Borges, K. S., Valera, F. C. P., Scrideli, C. A., Umezawa, K., & Tone, L. G. (2010). Antitumor effect of the dehydroxymethylepoxyquinomicin (DHMEQ), a novel nuclear factor-B inhibitor, in pediatric osteosarcoma cell lines. Pediatric Blood & Cancer. Hoboken: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo.NLM
Gamero AMC, Borges KS, Valera FCP, Scrideli CA, Umezawa K, Tone LG. Antitumor effect of the dehydroxymethylepoxyquinomicin (DHMEQ), a novel nuclear factor-B inhibitor, in pediatric osteosarcoma cell lines. Pediatric Blood & Cancer. 2010 ; 55. n. 5 931.[citado 2024 nov. 02 ]Vancouver
Gamero AMC, Borges KS, Valera FCP, Scrideli CA, Umezawa K, Tone LG. Antitumor effect of the dehydroxymethylepoxyquinomicin (DHMEQ), a novel nuclear factor-B inhibitor, in pediatric osteosarcoma cell lines. Pediatric Blood & Cancer. 2010 ; 55. n. 5 931.[citado 2024 nov. 02 ]